Table 3.
Currently recruiting trials and published phase I studies on new pharmacological treatment approaches.
| Publication | Study Type | Conditions | Intervention | Outcome | Phase Ⅱ Proposed |
|---|---|---|---|---|---|
| Becher et al., 2017 [96] | multicenter | pediatric solid tumors | perifosine, temsirolimus | well tolerated, no objective response | NA |
| Kieran et al., 2019 [95] | multicenter | BRAF V600E mutation positive pediatric tumors | dabrafenib | well tolerated | yes |
| Friedman et al., 2021 [88] | multicenter | pediatric HGG | HSV-1 G207 | well tolerated, objective change in tumor metabolism | yes |
| McCrea et al., 2021 [97] | multicenter | HGG and DIPG | intraarterial BEV and cetuximab with BBB disruption | well tolerated, little objective effect | yes |
| NCT04295759 | multicenter | pediatric HGG | INCB7839 | recruiting | NA |
| NCT04732065 | multicenter | pediatric brain tumors | ONC206 | recruiting | NA |
| NCT04655404 | multicenter | pediatric HGG | larotrectinib | recruiting | NA |
| NCT03615404 | single center | pediatric brain tumors | CMV-DC with GM-CSF | completed, publication pending | NA |
| NCT02208362 | single center | pediatric and adult glioma | IL13Ralpha2-CAR-T cells | active, not recruiting | NA |
HGG = high grade glioma; DIPG = diffuse intrinsic pontine glioma; BRAF V600E = v-Raf murine sarcoma viral oncogene homolog B1 V600E; BEV = bevacizumab; BBB = blood–brain barrier; INCB7839 = aderbasib; CMV-DC = cytomegalyvirus infected dentritic cells; GM-CSF = granulocyte macrophage colony stimulating factor.